文献速递血栓与止血

阿哌沙班治疗儿童静脉血栓栓塞:开放标签随机对照描述性试验

Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.
PubMed 文献 · Lancet Haematol · 2026-01-01

这项在14国120中心开展的开放标签随机对照描述性研究纳入229例<18岁静脉血栓栓塞患者,按2:1随机接受阿哌沙班或标准抗凝。固定剂量按体重分层阿哌沙班方案的安全性和有效性相似于标准治疗。

要点

  • 大出血及临床相关非大出血发生率两组均低,无大出血事件。
  • 固定剂量按体重分层阿哌沙班方案可用于儿童VTE治疗。

核心结论

  • 在<18岁儿童VTE患者中,固定剂量按体重分层阿哌沙班方案的安全性和有效性相似于标准抗凝治疗。

研究设计与样本

  • 前瞻性、开放标签、多中心、随机、对照描述性研究,在14国120中心开展,纳入229例<18岁经影像确认的VTE患者。
  • 患者按2:1随机分配至口服阿哌沙班(155例)或标准治疗(74例),按年龄分层,主要治疗期12周 optionally 延长6-12周。

主要发现

  • 任何级别不良事件发生率阿哌沙班131/152(86%)vs 标准治疗61/73(84%);常见事件为头痛(16% vs 15%)、鼻出血(16% vs 19%)、呕吐(13% vs 5%)。
  • 阿哌沙班组3例治疗相关严重不良事件(2例便血,1例脑静脉窦血栓),标准治疗组无;无治疗相关死亡。

临床怎么用

  • 对于<18岁儿童VTE患者,固定剂量按体重分层阿哌沙班可作为标准抗凝治疗之外的潜在治疗选择。

局限性

  • 研究为描述性设计,非优效性检验,样本量有限。
  • 开放标签设计可能引入偏倚,但终点由独立盲法委员会裁定。
  • 排除标准包括随机前标准抗凝>14天、活动性出血或高出血风险、基线肝功能异常或肾功能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary data show an increasing incidence of venous thromboembolism in children, yet there are few evidence-based treatment guidelines on direct oral anticoagulant use for venous thromboembolism in this population. We aimed to investigate the safety and efficacy of apixaban in paediatric patients with venous thromboembolism. METHODS: This prospective, open-label, multicentre, randomised, controlled descriptive study was conducted in 120 sites in 14 countries and included a 12-week main treatment phase followed by an optional 6-12-week extension in the apixaban treatment group for patients who required additional anticoagulation for their index event, were adherent to apixaban administration, and had completed all study visits and activities. Patients were eligible if they were younger than 18 years with an index venous thromboembolism event confirmed by the investigator via imaging and were currently tolerating enteric medications. Exclusion criteria included more than 14 days of standard-of-care anticoagulant treatment before random assignment, active bleeding or a high risk of bleeding, and baseline abnormal liver function or inadequate kidney function. Patients were randomly assigned 2:1 to oral apixaban or standard-of-care (unfractionated heparin, low-molecular-weight heparin, or vitamin K antagonists) per local practice via a central randomisation and drug assignment system (stratified by age). The study used a fixed-dose-by-bodyweight-tier oral apixaban regimen (with nasogastric or gastric feeding, if required). Neonates initiated 0·1 mg oral apixaban twice daily for days 1-7, with the dose remaining at 0·1 mg twice daily thereafter unless otherwise indicated by the results of pharmacokinetics analysis on day 1. For children aged 28 days or older, doses ranged from 0·6 mg twice daily for the first 7 days and 0·3 mg thereafter (4 kg to <5 kg tier) and 10 mg twice daily for the first 7 days and 5 mg twice daily thereafter (highest weight tier, ≥35 kg). The primary efficacy endpoint was a composite of incidence of recurrent venous thromboembolism and venous thromboembolism-related mortality during the main phase (analysed in all randomly assigned patients). The primary safety endpoint was a composite of major bleeding and clinically relevant non-major bleeding during the main phase (analysed in all randomly assigned and treated patients). Efficacy and safety endpoints were adjudicated by an independent committee whose members were masked to treatment assignment. Adverse events were monitored using a combination of solicited and unsolicited event collection. The study is registered with ClinicalTrials.gov (NCT02464969) and is complete. FINDINGS: Between Nov 22, 2015, and April 30, 2024, 229 patients were randomly assigned: 155 to apixaban and 74 to standard of care. Median age was 14·2 years (IQR 6·1-16·5), with 137 (60%) patients age 12 years to younger than 18 years, 44 (19%) age 2 years to younger than 12 years, 32 (14%) age 28 days to younger than 2 years, and 16 (7%) age 27 days or younger. 128 (56%) patients were female, 101 (44%) were male, and 175 (76%) were White. Median treatment duration during the main phase was 83 days (IQR 78-90) in the apixaban group and 83 days (77-86) in the standard-of-care group. The primary efficacy endpoint occurred in four (2·6% [95% CI 0·8-6·7]) of 155 patients assigned to apixaban and two (2·7% [0·2-9·9]) of 74 assigned to standard of care; all events were recurrent venous thromboembolism. The primary safety endpoint occurred in two (1·3% [0·1-5·0]) of 152 apixaban-treated patients and one (1·4% [0·0-8·1]) of 73 standard-of-care-treated patients; all events were clinically relevant non-major bleeding, with no major bleeding events. Rates of any-grade adverse events were numerically similar in the apixaban (131 [86%] of 152 patients) and standard-of-care (61 [84%] of 73]) groups. The most common events were headache (25 [16%] in the apixaban group vs 11 [15%] in the standard-of-care group), epistaxis (24 [16%] vs 14 [19%]), and vomiting (20 [13%] vs four [5%]). There were three treatment-related serious adverse events with apixaban (two [1%] participants with haematochezia and one [1%] with cerebral venous sinus thrombosis) and none with standard of care. There were no treatment-related deaths during the study. INTERPRETATION: In this descriptive study, the safety and efficacy profile of a fixed-dose-by-bodyweight-tier apixaban regimen was similar to that of standard of care for the treatment of venous thromboembolism and prevention of venous thromboembolism recurrence in children younger than 18 years, providing a potential additional treatment option in this patient population. FUNDING: Pfizer and Bristol Myers Squibb.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Brandão LR, Driscoll J, Newburger JW, et al. Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial. Lancet Haematol. 2026. PMID: 42392108. doi:10.1016/S2352-3026(26)00107-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。